Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Study Review Shows CoQ10 and Pine Bark Synergistically Enhance Cardiovascular Health
Assessment published in the February issue of Evidence Based Integrative Medicine observes that patients who supplemented with the pine tree bark extract known as Pycnogenol® and CoQ10 in combination benefited from the collaborative antioxidant effects.
- Study Review Shows CoQ10 and Pine Bark Synergistically Enhance Cardiovascular Health
Assessment published in the February issue of Evidence Based Integrative Medicine observes that patients who supplemented with the pine tree bark extract known as Pycnogenol® and CoQ10 in combination benefited from the collaborative antioxidant effects.
- Study Review Shows CoQ10 and Pine Bark Synergistically Enhance Cardiovascular Health
Assessment published in the February issue of Evidence Based Integrative Medicine observes that patients who supplemented with the pine tree bark extract known as Pycnogenol® and CoQ10 in combination benefited from the collaborative antioxidant effects.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- New Study Suggests Link Between Tocotrienol and Inhibition of Cancer Cell Proliferation - Anti-Angiogenic Activity
Research published in Biochemical and Biophysical Research Communication, (2006 (339), 949-955) suggests that tocotrienols may act as potent anti-cancer agents by inhibiting pol lambda and angiogenesis.
- UC Davis Study Shows Grape Seed Extract May Be Effective in Reducing Blood Pressure
One month study was done on 24 male and female patients diagnosed with metabolic syndrome indicates that supplementation with new patent-pending grape seed extract developed and made by Polyphenolics correlates with reduced blood pressure and at higher concetrations, a drop in serum oxidized LDL cholesterol levels was observed.
- UC Davis Study Shows Grape Seed Extract May Be Effective in Reducing Blood Pressure
One month study was done on 24 male and female patients diagnosed with metabolic syndrome indicates that supplementation with new patent-pending grape seed extract developed and made by Polyphenolics correlates with reduced blood pressure and at higher concetrations, a drop in serum oxidized LDL cholesterol levels was observed.
- UC Davis Study Shows Grape Seed Extract May Be Effective in Reducing Blood Pressure
One month study was done on 24 male and female patients diagnosed with metabolic syndrome indicates that supplementation with new patent-pending grape seed extract developed and made by Polyphenolics correlates with reduced blood pressure and at higher concetrations, a drop in serum oxidized LDL cholesterol levels was observed.
- UC Davis Study Shows Grape Seed Extract May Be Effective in Reducing Blood Pressure
One month study was done on 24 male and female patients diagnosed with metabolic syndrome indicates that supplementation with new patent-pending grape seed extract developed and made by Polyphenolics correlates with reduced blood pressure and at higher concetrations, a drop in serum oxidized LDL cholesterol levels was observed.
- UC Davis Study Shows Grape Seed Extract May Be Effective in Reducing Blood Pressure
One month study was done on 24 male and female patients diagnosed with metabolic syndrome indicates that supplementation with new patent-pending grape seed extract developed and made by Polyphenolics correlates with reduced blood pressure and at higher concetrations, a drop in serum oxidized LDL cholesterol levels was observed.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Plants Help Fight Cardiovascular Disorders
On the occasion of the XIV International Symposium on Atherosclerosis in Rome, Paolo Morazzoni, President of the Scientific Board of Indena, is to give a Master Lecture on how standardised extracts of edible plants can be used to optimise nutrition.
- Preliminary Data from Human Clinical Trial Shows Vectomega®, Has Positive Results in Numerous Areas of Health
Preliminary findings from a recent human trial by French doctors demonstrate that 2 tablets per day of Vectomega® improve cardiovascular health by reducing cholesterol, triglycerides and increasing HDL-c in a healthy population, among other benefits.
- Preliminary Data from Human Clinical Trial Shows Vectomega®, Has Positive Results in Numerous Areas of Health
Preliminary findings from a recent human trial by French doctors demonstrate that 2 tablets per day of Vectomega® improve cardiovascular health by reducing cholesterol, triglycerides and increasing HDL-c in a healthy population, among other benefits.
- Preliminary Data from Human Clinical Trial Shows Vectomega®, Has Positive Results in Numerous Areas of Health
Preliminary findings from a recent human trial by French doctors demonstrate that 2 tablets per day of Vectomega® improve cardiovascular health by reducing cholesterol, triglycerides and increasing HDL-c in a healthy population, among other benefits.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Reduction of Inducible Arrhythmia in Patients with Cardiovascular Disease by Fish Oil
Dr. R. Metcalf presented highly original findings this morning on DHA/EPA Omega-3 fatty acids and cardiac arrhythmias from a recent pilot trial.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Fish Oil Provides 24-Hour Control of Circulating Fat Levels
The research study, reported in Cairns, Australia by Professor Bruce Holub at the Congress for the International Society for the study of Fatty Acids and Lipids, evaluated the effect of supplementation with DHA/EPA omega-3 fatty acids from fish oil on blood triglyceride levels throughout the 24-hour period. Findings indicate that DHA/EPA omega-3 fatty acid supplementation, taken daily in the morning or evening on a regular basis, can provide 24-hour risk reduction of blood triglyceride levels before, between, and after meals.
- Results of Jarrow Formulas’ Co-Q10 Study Published in European Heart Journal
The results of a clinical trial investigating the effects of Jarrow Formulas® Q-absorb(TM)on chronic heart failure patients was recently published in the European Heart Journal. In the study, Italian scientists from the Lancisi Heart Institute and the University of Ancona (Institute of Biochemistry) measured the effects of 300 mg per day (100 mg T.I.D.) Q-absorb(TM) on the cardiovascular functional capacity of 23 heart patients.
- Results of Jarrow Formulas’ Co-Q10 Study Published in European Heart Journal
The results of a clinical trial investigating the effects of Jarrow Formulas® Q-absorb(TM)on chronic heart failure patients was recently published in the European Heart Journal. In the study, Italian scientists from the Lancisi Heart Institute and the University of Ancona (Institute of Biochemistry) measured the effects of 300 mg per day (100 mg T.I.D.) Q-absorb(TM) on the cardiovascular functional capacity of 23 heart patients.
- Results of Jarrow Formulas’ Co-Q10 Study Published in European Heart Journal
The results of a clinical trial investigating the effects of Jarrow Formulas® Q-absorb(TM)on chronic heart failure patients was recently published in the European Heart Journal. In the study, Italian scientists from the Lancisi Heart Institute and the University of Ancona (Institute of Biochemistry) measured the effects of 300 mg per day (100 mg T.I.D.) Q-absorb(TM) on the cardiovascular functional capacity of 23 heart patients.
- Study shows unique garlic product works like the real thing
A study presented at the Annual Meeting of the American College of Nutrition today suggests that a new proprietary garlic product developed by Nutra Products, Inc., Garli-Eze®, delivers allicin, the key bioactive ingredient of garlic, to the body in amounts equal to that of fresh high allicin garlic macerate and yielded no unsocial responses due to chewing fresh garlic.
- Study shows unique garlic product works like the real thing
A study presented at the Annual Meeting of the American College of Nutrition today suggests that a new proprietary garlic product developed by Nutra Products, Inc., Garli-Eze®, delivers allicin, the key bioactive ingredient of garlic, to the body in amounts equal to that of fresh high allicin garlic macerate and yielded no unsocial responses due to chewing fresh garlic.
- Study shows unique garlic product works like the real thing
A study presented at the Annual Meeting of the American College of Nutrition today suggests that a new proprietary garlic product developed by Nutra Products, Inc., Garli-Eze®, delivers allicin, the key bioactive ingredient of garlic, to the body in amounts equal to that of fresh high allicin garlic macerate and yielded no unsocial responses due to chewing fresh garlic.
- Study shows unique garlic product works like the real thing
A study presented at the Annual Meeting of the American College of Nutrition today suggests that a new proprietary garlic product developed by Nutra Products, Inc., Garli-Eze®, delivers allicin, the key bioactive ingredient of garlic, to the body in amounts equal to that of fresh high allicin garlic macerate and yielded no unsocial responses due to chewing fresh garlic.
- Clinical Trial Shows Liquid Eggs Enriched With Omega-3 Deliver Heart Health Benefits
Results of a clinical trial published this month in Food Research International indicate that eating omega-3 enriched liquid eggs can improve blood triglyceride levels, boost heart health, and help families reach their daily recommended intake of omega-3.
- Clinical Trial Shows Liquid Eggs Enriched With Omega-3 Deliver Heart Health Benefits
Results of a clinical trial published this month in Food Research International indicate that eating omega-3 enriched liquid eggs can improve blood triglyceride levels, boost heart health, and help families reach their daily recommended intake of omega-3.
- Clinical Trial Shows Liquid Eggs Enriched With Omega-3 Deliver Heart Health Benefits
Results of a clinical trial published this month in Food Research International indicate that eating omega-3 enriched liquid eggs can improve blood triglyceride levels, boost heart health, and help families reach their daily recommended intake of omega-3.
- Clinical Trial Shows Liquid Eggs Enriched With Omega-3 Deliver Heart Health Benefits
Results of a clinical trial published this month in Food Research International indicate that eating omega-3 enriched liquid eggs can improve blood triglyceride levels, boost heart health, and help families reach their daily recommended intake of omega-3.
- Study Sheds Light on Soy and Heart Health
According to a study published in the journal Maturitas, Chilean researchers recruited post-menopausal women to take part in the double-blind, randomized, placebo-controlled study, randmoly assigning participants to receive a daily supplement of 100 mg isoflavones or an identical placebo for three months. At the end of the three-month period, the group receiving the isoflavone supplement showed a significant decrease in the density of a particular platelet receptor (known as TxA2), while the placebo group remained mostly unchanged.
- Study Sheds Light on Soy and Heart Health
According to a study published in the journal Maturitas, Chilean researchers recruited post-menopausal women to take part in the double-blind, randomized, placebo-controlled study, randmoly assigning participants to receive a daily supplement of 100 mg isoflavones or an identical placebo for three months. At the end of the three-month period, the group receiving the isoflavone supplement showed a significant decrease in the density of a particular platelet receptor (known as TxA2), while the placebo group remained mostly unchanged.
- Study Sheds Light on Soy and Heart Health
According to a study published in the journal Maturitas, Chilean researchers recruited post-menopausal women to take part in the double-blind, randomized, placebo-controlled study, randmoly assigning participants to receive a daily supplement of 100 mg isoflavones or an identical placebo for three months. At the end of the three-month period, the group receiving the isoflavone supplement showed a significant decrease in the density of a particular platelet receptor (known as TxA2), while the placebo group remained mostly unchanged.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- New Study Suggests Plant Sterol-Enriched Chocolate Snack Bars Support Heart Health
Study published in the November issue of the Journal of the American Dietetic Association invoved 67 men and women with elevated cholesterol (> 200 mg/dl total cholesterol) who were randomly assigned to consume either the CocoaVia(R) snack bar twice daily, or a placebo product (matched in its design but formulated without plant sterols) for 6 weeks. At the end of 6 weeks, total cholesterol levels had decreased, on average, by 4.7 percent, and LDL levels, on average, had decreased by 6 percent in the group who regularly consumed the CocoaVia(R) snack bar formulated with plant sterols.
- Next Pharmaceuticals Presents Study Results on Flavoxine(TM) Ingredient
Double-blind placebo-controlled clinical trial with 80 subjects indicated that Flavoxine(TM), a blend of two plant extracts, a proprietary extract of Phellodendron amurense and a patented (U.S. Patent No. 6,987,125) extract of orange peel containing polymethoxylated flavones, significantly increased HDL-cholesterol, while significantly reducing LDL-cholesterol.
- Next Pharmaceuticals Presents Study Results on Flavoxine(TM) Ingredient
Double-blind placebo-controlled clinical trial with 80 subjects indicated that Flavoxine(TM), a blend of two plant extracts, a proprietary extract of Phellodendron amurense and a patented (U.S. Patent No. 6,987,125) extract of orange peel containing polymethoxylated flavones, significantly increased HDL-cholesterol, while significantly reducing LDL-cholesterol.
- Next Pharmaceuticals Presents Study Results on Flavoxine(TM) Ingredient
Double-blind placebo-controlled clinical trial with 80 subjects indicated that Flavoxine(TM), a blend of two plant extracts, a proprietary extract of Phellodendron amurense and a patented (U.S. Patent No. 6,987,125) extract of orange peel containing polymethoxylated flavones, significantly increased HDL-cholesterol, while significantly reducing LDL-cholesterol.
- Natural Vitamin K2 Supplement MenaQ7 Shown to be Superior to K1 in A New Human Study in the Journal Blood
Scientists at the Cardiovascular Research Institute (CARIM) and VitaK, Maastricht University, The Netherlands, demonstrated a significant superiority of Natural Vitamin K2 as Mk-7 in four different human models. They cited the major difference between the vitamin K species as the very long half-life time of Mk-7, which results in much more stable blood levels and 7 to 8 times greater accumulation of Mk-7 in the blood. Mk-7 also more effectively promoted and activated markers of bone building and showed a marked advantage against vitamin K antagonists.
- Natural Vitamin K2 Supplement MenaQ7 Shown to be Superior to K1 in A New Human Study in the Journal Blood
Scientists at the Cardiovascular Research Institute (CARIM) and VitaK, Maastricht University, The Netherlands, demonstrated a significant superiority of Natural Vitamin K2 as Mk-7 in four different human models. They cited the major difference between the vitamin K species as the very long half-life time of Mk-7, which results in much more stable blood levels and 7 to 8 times greater accumulation of Mk-7 in the blood. Mk-7 also more effectively promoted and activated markers of bone building and showed a marked advantage against vitamin K antagonists.
- Natural Vitamin K2 Supplement MenaQ7 Shown to be Superior to K1 in A New Human Study in the Journal Blood
Scientists at the Cardiovascular Research Institute (CARIM) and VitaK, Maastricht University, The Netherlands, demonstrated a significant superiority of Natural Vitamin K2 as Mk-7 in four different human models. They cited the major difference between the vitamin K species as the very long half-life time of Mk-7, which results in much more stable blood levels and 7 to 8 times greater accumulation of Mk-7 in the blood. Mk-7 also more effectively promoted and activated markers of bone building and showed a marked advantage against vitamin K antagonists.
- Natural Vitamin K2 Supplement MenaQ7 Shown to be Superior to K1 in A New Human Study in the Journal Blood
Scientists at the Cardiovascular Research Institute (CARIM) and VitaK, Maastricht University, The Netherlands, demonstrated a significant superiority of Natural Vitamin K2 as Mk-7 in four different human models. They cited the major difference between the vitamin K species as the very long half-life time of Mk-7, which results in much more stable blood levels and 7 to 8 times greater accumulation of Mk-7 in the blood. Mk-7 also more effectively promoted and activated markers of bone building and showed a marked advantage against vitamin K antagonists.
- New research shows Beneo(TM) prebiotics could improve heart health
research published in the British Journal of Nutrition on mice with a predisposition to heart disease, showed that diets supplemented with Beneo(TM)Synergy1 or Beneo(TM)HP inhibited the build-up of fatty deposits in the animals’ arteries.
suggests
- New research shows Beneo(TM) prebiotics could improve heart health
research published in the British Journal of Nutrition on mice with a predisposition to heart disease, showed that diets supplemented with Beneo(TM)Synergy1 or Beneo(TM)HP inhibited the build-up of fatty deposits in the animals’ arteries.
suggests
- New research shows Beneo(TM) prebiotics could improve heart health
research published in the British Journal of Nutrition on mice with a predisposition to heart disease, showed that diets supplemented with Beneo(TM)Synergy1 or Beneo(TM)HP inhibited the build-up of fatty deposits in the animals’ arteries.
suggests
- Nutri Pharma research on the detrimental effects of UHT processing of Soy protein published(1)
A recently published placebo-controlled, randomised, double-blind clinical study over 4 weeks (80 persons) carried out in conjunction with the Karolinska Institute in Stockholm and the University of Potsdam has found that soy protein products which have been UHT treated lose their ability to reduce serum cholesterol, and can significantly increase the levels of harmful LDL cholesterol.
- Nutri Pharma research on the detrimental effects of UHT processing of Soy protein published(1)
A recently published placebo-controlled, randomised, double-blind clinical study over 4 weeks (80 persons) carried out in conjunction with the Karolinska Institute in Stockholm and the University of Potsdam has found that soy protein products which have been UHT treated lose their ability to reduce serum cholesterol, and can significantly increase the levels of harmful LDL cholesterol.
- Nutri Pharma research on the detrimental effects of UHT processing of Soy protein published(1)
A recently published placebo-controlled, randomised, double-blind clinical study over 4 weeks (80 persons) carried out in conjunction with the Karolinska Institute in Stockholm and the University of Potsdam has found that soy protein products which have been UHT treated lose their ability to reduce serum cholesterol, and can significantly increase the levels of harmful LDL cholesterol.
- Nutri Pharma research on the detrimental effects of UHT processing of Soy protein published(1)
A recently published placebo-controlled, randomised, double-blind clinical study over 4 weeks (80 persons) carried out in conjunction with the Karolinska Institute in Stockholm and the University of Potsdam has found that soy protein products which have been UHT treated lose their ability to reduce serum cholesterol, and can significantly increase the levels of harmful LDL cholesterol.
- Nutri Pharma research on the detrimental effects of UHT processing of Soy protein published(1)
A recently published placebo-controlled, randomised, double-blind clinical study over 4 weeks (80 persons) carried out in conjunction with the Karolinska Institute in Stockholm and the University of Potsdam has found that soy protein products which have been UHT treated lose their ability to reduce serum cholesterol, and can significantly increase the levels of harmful LDL cholesterol.
- Study Indicates That Martek's Algal DHA Lowers Triglycerides
An independent study published in the current issue of Journal of the American College of Nutrition indicates that the company's life'sDHA(TM) from microalgae is effective in helping to reduce triglycerides in patients with coronary artery disease and elevated triglycerides.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
LIBERTY CORNER, N.J., Aug. 17 /PRNewswire/ -- Reliant Pharmaceuticals today announced the publication of new data in the July edition of the Journal of Clinical Pharmacology finding the co-administration of Omacor (omega-3-acid ethyl esters) with simvastatin has minimal interaction between the two drugs. Omacor (4 g) plus simvastatin (80 mg) did not significantly affect the steady-state pharmacokinetics of simvastatin and was well-tolerated in healthy patients.(1)
Omacor is the first and only Food and Drug Administration (FDA)-approved omega-3 fatty acid. Omacor was approved by the FDA in November 2004 as an adjunct to diet to reduce very high triglyceride levels (greater than or equal to 500 mg/dL) in adult patients.(2) At that time, Reliant Pharmaceuticals also received an FDA New Drug Application (NDA) approvable letter for Omacor in combination with a statin to treat high triglyceride levels (200-499 mg/dL) in adult patients. To gain final approval, Reliant is conducting a clinical trial to evaluate the efficacy and safety of Omacor as adjunctive therapy to simvastatin for the treatment of high triglycerides.(3)
"Many Americans who receive statin therapy continue to have elevated triglycerides. It's important to evaluate the safety and efficacy of Omacor as adjunctive therapy in these patients," said Robert Shalwitz, MD, Vice President of Clinical Development, Reliant Pharmaceuticals. "Reliant Pharmaceuticals is committed to patient safety and ongoing research for the effective use of Omacor."
About the Study
The open-label, randomized, 2-way crossover, drug-drug interaction study evaluated the impact of Omacor capsules on plasma simvastatin pharmacokinetics in 24 healthy patients. Patients were given 4 g of Omacor co-administered with 80 mg of simvastatin or 80 mg of simvastatin alone.(4) The primary pharmacokinetic end points for the determination of drug interaction were AUC (area under the plasma concentration-time curve over the final 0-24 hour dosing interval) and C(max) (maximum plasma concentration over the final dosing interval) on day 14.(5)
After 14 days of dosing, both the extent and rate of exposure to simvastatin and its major active metabolite, beta-hydroxy simvastatin, were similar after co-administration of Omacor and simvastatin compared with administration of simvastatin alone. Additionally, after single-dose administration, rates of exposure (C(max)) following either treatment were similar for both simvastatin and its beta-hydroxy metabolite. With single dosing, the AUC of simvastatin, but not that of its beta-hydroxy metabolite, increased (by 19% for AUC(0-t) and 24% for AUC(inf)) when Omacor and simvastatin were co-administered.(6)
Important Information About Omacor
* Omacor is used along with diet to reduce very high triglycerides in
adult patients. Before taking Omacor your healthcare provider should
help you try to control your high triglyceride level by:
-- Exercising and losing weight if you are overweight.
-- Decreasing alcohol use.
-- Controlling medical problems that can cause high triglyceride
levels (such as diabetes mellitus and hypothyroidism).
-- Stopping or changing medicines that can increase triglyceride
levels (such as estrogens, thiazide diuretics, beta blockers).
* Omacor should be used with caution in people allergic to fish.
Treatment to reduce very high triglyceride levels may result in
elevations in LDL-C and non-HDL-C in some individuals. The effect of
Omacor on cardiovascular morbidity and mortality in patients with very
high triglyceride levels has not been determined.
* Tell your healthcare provider about all your medical conditions,
including if you have liver problems, are pregnant, are trying to
become pregnant or are breast-feeding. Tell your healthcare provider
if you take blood thinners. If you take both Omacor and a blood
thinner, your healthcare provider should check you occasionally to see
if an effect has occurred.
* Some possible side effects of Omacor include belching, infection, flu
symptoms, upset stomach, rash and change in your sense of taste. This
is not a complete list Omacor side effects.
* For more detailed information about Omacor, ask your healthcare
provider or go to http://www.omacorrx.com.
About Reliant Pharmaceuticals
Reliant Pharmaceuticals is a pharmaceutical company with integrated sales, marketing and development expertise that markets a portfolio of branded cardiovascular pharmaceutical products. Reliant focuses on marketing promotionally sensitive pharmaceutical products to the high prescribing primary care, cardiovascular and specialist physician markets in the United States. Reliant also acquires rights to and develops product candidates in mid- to late-stage clinical development. Reliant's sales force infrastructure is comprised of approximately 850 sales professionals nationwide.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission.
References:
(1) McKenney J, Swearingen D, Di Spirito M, Doyle R, Pantaleon C, Kling
D, Shalwitz R. Study of the Pharmacokinetic Interaction Between
Simvastatin and Prescription Omega-3-Acid Ethyl Esters. J Clin
Pharmacol. 2006; 46:785-791.
(2) OMACOR Prescribing Information, Liberty Corner, NJ: Reliant
Pharmaceuticals, Inc.; 2005.
(3) Data on file. Reliant Pharmaceuticals, Inc.
(4) McKenney J, Swearingen D, Di Spirito M, Doyle R, Pantaleon C, Kling
D, Shalwitz R. Study of the Pharmacokinetic Interaction Between
Simvastatin and Prescription Omega-3-Acid Ethyl Esters. J Clin
Pharmacol. 2006; 46:785-791.
(5) Ibid
(6) Ibid |